Yonhap Infomax NewsGI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.
#YonhapInfomax #GIInnovation #Merck #ImmunoOncology #Keytruda #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65767
#YonhapInfomax #GIInnovation #Merck #ImmunoOncology #Keytruda #TechnologyTransfer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=65767
GI Innovation Nears Major Licensing Deal With Pharma Giant Merck
GI Innovation is set to sign South Korea’s first immuno-oncology technology licensing deal with Merck, potentially marking a milestone for the domestic biotech sector as talks near completion for GI-101 and GI-102 combination with Keytruda.